

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 123439		APPLICATION NO. 10/530,568	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Eric ADRIAENSSENS et al.			
				FILING DATE April 7, 2005		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
MH	1	WO 94/06935 A1	3/31/1994	WIPO			
↓	2	FR 2 781 802 B1	5/11/2001	FRANCE			
	3	WO 95/08000	3/23/1995	WIPO			
	4	WO 03/076942 A2	9/18/2003	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
MH	5	BASUYAU et al., "Standards, Options and Recommendations (SOR) for Tumor Markers in Breast Cancer," <i>Bull Cancer</i> 2000, no. 87, pp. 723-737 (2000)					
	6	SPRINGER, "Immunoreactive T and Tn Epitopes in Cancer Diagnosis, Prognosis, and Immunotherapy," <i>J. Mol. Med.</i> , no. 75, pp. 594-602 (1997)					
	7	GNJACTIC et al., "Accumulation of the p53 Protein Allows Recognition by Human CTL of a Wild-Type p53 Epitope Presented by Breast Carcinomas and Melanomas," <i>Journal of Immunology</i> , no. 160, pp. 328-333 (1998)					
	8	DISIS et al., "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," <i>Adv Cancer Res.</i> , no. 71, pp. 343-371 (1997)					
	9	JAGER et al., "Cancer-testis Antigens and ING1 Tumor Suppressor Gene Product are Breast Cancer Antigens: Characterization of Tissue-Specific ING1 Transcripts and a Homologue Gene," <i>Cancer Research</i> , no. 59; pp. 6197-6204 (1999)					
	10	JAGER et al., "Identification of a Tissue-Specific Putative Transcription Factor in Breast Tissue by Serological Screening of a Breast Cancer Library," <i>Cancer Research</i> , no. 61, pp. 2055-2061 (2001)					
↓	11	SCANLAN et al., "Challenges to the Development of Antigen-Specific Breast Cancer Vaccines," <i>Breast Cancer Research</i> , no. 3, pp. 95-98 (2001)					
	12	DESCAMPS et al., "Nerve Growth Factor is Mitogenic for Cancerous But Not Normal Human Breast Epithelial Cells," <i>The Journal of Biological Chemistry</i> , vol. 273, no. 27, pp. 16659-16662 (July 3, 1998)					
	13	DESCAMPS et al., "Nerve Growth Factor Stimulates Proliferation and Survival of Human Breast Cancer Cells Through Two Distinct Signaling Pathways," <i>The Journal of Biological Chemistry</i> , vol. 276, no. 21, pp. 17864-17870 (May 25, 2001)					
	14	LEVI-MONTALCINI et al., "The Nerve Growth Factor 35 Years Later," <i>Science</i> , vol. 237, pp. 1154-1162 (1987)					
	15	TORCIA et al., "Nerve Growth Factor is an Autocrine Survival Factor for Memory B Lymphocytes," <i>Cell</i> , vol. 85, pp. 345-356 (May 3, 1996)					
EXAMINER					DATE CONSIDERED		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Date: July 6, 2005

Form PTO-1449 (REV. 8-83)		US Dept. of Commerce PATENT & TRADEMARK OFFICE		ATTY DOCKET NO. 123439		APPLICATION NO. 10/530,568	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Eric ADRIAENSSENS et al. FILING DATE April 7, 2005			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
MH 	16	DESCAMPS et al., "Expression of Nerve Growth Factor Receptors and Their Prognostic Value in Human Breast Cancer," <i>Cancer Research</i> , no. 61, pp. 4337-4340 (June 1, 2001)					
	17	BONINI et al., "Circulating Nerve Growth Factor Levels are Increased in Humans with Allergic Diseases and Asthma," <i>Proc. Natl. Acad. Sci. USA</i> , vol. 93, pp. 10955-10960 (October 1996)					
	18	CHEVALIER et al., "Biotin and Digoxigenin as Labels for Light and Electron Microscopy in Situ Hybridization Probes: Where Do We Stand?" <i>The Journal of Histochemistry & Cytochemistry</i> , vol. 45, no. 4, pp. 481-491 (1997)					
	19	PATTERSON, "Mass Spectrometry and Proteomics," <i>Physiological Genomics</i> 2, pp. 59-65 (2000)					
	20	METEZEAU et al., <i>La Cytometrie En Flux</i> , vol. 1, Medsi/McGraw-Hill Publications, pp. 21-74 (before October 2003)					
	21	<i>Intracellular Flow Cytometry: Applied Reagents and Techniques</i> , pp. 1-21, BD Pharmingen (October 2000)					
	22	HONDERMARCK et al., "Early Changes in Protein Synthesis Induced by Basis Fibroblast Growth Factor, Nerve Growth Factor, and Epidermal Growth Factor in PC12 Pheochromocytoma Cells," <i>Proc. Natl. Acad. Sci. USA</i> , vol. 91, pp. 9377-9381 (September 1994)					
	23	HATTORI et al., "Tumor Necrosis Factor Stimulates the Synthesis and Secretion of Biologically Active Nerve Growth Factor in Non-neuronal Cells," <i>The Journal of Biological Chemistry</i> , vol. 268, no. 4, pp. 2577-2582 (February 5, 1993)					
	24	KUMAR et al., "The first Analogues of LNA (Locked Nucleic Acids): Phosphorothioate-LNA and 2'-Thio-LNA," <i>Bioorganic & Medicinal Chemistry Letters</i> , vol. 8, Issue 16, pp. 2219-2222 (August 18, 1998)					
	25	EGHOLM et al., "Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone," <i>J. Am. Chem. Soc.</i> , no. 114, pp. 1895-1897 (1992)					
	26	TAPLEY et al., "K252a is a Selective Inhibitor of the Tyrosine Protein Kinase Activity of the <i>trk</i> Family of Oncogenes and Neurotrophin Receptors," <i>Oncogene</i> , no. 7, pp. 371-381 (1992)					
	27	DYKXHOORN et al., "Killing the Messenger: Short RNAs that Silence Gene Expression," <i>Nature Review</i> , vol. 4, pp. 457-467 (June 2003)					
28	MALECK et al., "Methods in Molecular Biology", no. 28, Ch. 36, Ed P.G. Issac, Humana Press, Inc., Totowa, NJ (1994)						
EXAMINER /Mark Halvorson/					DATE CONSIDERED 01/19/2007		
Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							